At a glance
- Originator Novo Nordisk
- Developer Helsinn Therapeutics; Novo Nordisk
- Class Hormones; Oligopeptides; Small molecules
- Mechanism of Action Growth hormone releasing factor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Gastrointestinal motility disorders; Postoperative ileus
- Discontinued Growth disorders
Most Recent Events
- 20 May 2011 Helsinn Therapeutics initiates enrolment in a phase IIb trial for Postoperative ileus in USA (NCT01280344)
- 28 Jan 2009 Sapphire Therapeutics has been acquired and merged into Helsinn
- 20 Feb 2007 Phase-I/II clinical trials in Postoperative ileus in USA (IV-infusion)